FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2585686985> ?p ?o ?g. }

• W2585686985 abstract "Abstract Reports in adults have shown that a BCR-ABL1 IS <10% at 3 months after the start of imatinib (IM) can predict better clinical outcome in chronic myeloid leukemia (CML). Recently, early molecular response (EMR) at 3 months has also been reported to correlate with better progression-free survival (PFS) in children treated with IM at a standard dose (260 mg/m2/day) (Millot et al, 2014). In order to confirm the relevance of this cut-off in the pediatric population treated with high-dose IM, we investigated the impact a cohort of children and adolescents with CML in chronic phase (CP) followed at 11 Italian Centers. Forty-four of 53 CP-CML patients treated with IM at a dose of 340 mg/m2/day who had available BCR-ABL1 levels at 3 months and had been followed for at least 12 months were included in this analysis. Cytogenetics were planned on bone marrow (BM) cells before and during IM therapy as well as molecular analysis on peripheral blood (PB) monthly and on BM every 3 months. Complete cytogenetic response (CCyR) was defined as the absence of Ph+ metaphases. Peripheral blood BCR-ABL1 levels were measured by quantitative RT-PCR assay expressed as International Scale (IS). Major molecular response (MMR) was defined as ≤0.1% BCR-ABL1 IS, while molecular response (MR) was considered as ≤0.01% BCR-ABL1 IS. Complete molecular response (CMR) was used to indicate levels of disease ≤0.0032% BCR-ABL1 IS or undetectable. BCR-ABL1 transcript levels <10% 3 months after starting IM were considered as EMR and were used to assess the association between EMR and the rates of: a) BCR-ABL1 IS <1% and CCyR after 6 months of IM treatment; b) MMR at 12 months; c) CCyR at 6 months; d) overall CCyR, MMR and CMR, as well as the association between EMR and PFS. Forty-four CP-CML patients - females: 17, males: 27; median age at diagnosis: 11.2 years (range: 3.1-15,8); median follow-up: 73.5 months (range:15-151.3) who had received IM at a median dose of 300 mg/m2/day (range: 140-380) were evaluable for molecular response. At 3 months of IM treatment, BCR-ABL1 transcript levels <10% and ≥10% were found in 79.5% and 20.5% of patients, respectively. The median administered dose of IM was similar (300 mg/m2 and 314 mg/m2 in patients with BCR-ABL1 IS <10% and ≥10%, respectively). At 6 months, 82% and 64% of evaluable patients showed CCyR and BCR-ABL1 transcript levels <1%, respectively. BCR-ABL1 transcript levels <0.1% were found in 63.5% of patients evaluable at 12 months. Overall, 92.5%, 85% and 39% of patients achieved CCyR, MMR and CMR, respectively. The correlations between BCR-ABL1 transcript levels <10% and ≥10% at 3 months and the rates of BCR-ABL1 IS <1% at 6 months and <0.1% at 12 months, CCyR at 6 months, overall CCyR, MMR and CMR are detailed in Fig 1. At 6 months, patients with BCR-ABL1 IS <10% after 3 months of IM had significantly higher response rates compared to those with BCR-ABL1 IS ≥10% (P = .031 and P.003 for CCyR and BCR-ABL1 IS <1%, respectively). Patients with EMR achieved higher rates of BCR-ABL1 IS <0.1% at 12 months as well as a better overall CCyR, MMR and CMR, though no statistically significant differences were found except for MMR (P =.041). With an overall PFS at 72 months of 91.4% (95% CI, 54.2-81.6), patients withBCR-ABL1 IS <10% at 3 months had a PFS similar to that of those with higher transcript levels. This might in part be explained by the high proportion (80%) of children who achieved a BCR-ABL1 IS <10% cut-off at 3 months. This response rate, higher than that (63%) reported by Millot in children treated with IM at a lower dose, is probably due to the higher dose of the drug utilized in our patients. In conclusion, the high-doses of IM used in our study allowed to achieve better short and long term results in childhood CP-CML than those reported with lower doses of IM (Millot et al, 2014). Using such doses, the prognostic impact of a BCR-ABL1 IS <10% cut-off after 3 months of IM treatment as a surrogate marker of response at 1 year and PFS is not confirmed. Disclosures Saglio: BMS: Consultancy, Other: Fees for occasional speeches; Novartis: Consultancy, Other: Fees for occasional speeches; Pfizer: Consultancy, Other: Fees for occasional speeches ; ARIAD: Consultancy, Other: Fees for occasional speeches." @default.
• W2585686985 created "2017-02-10" @default.
• W2585686985 creator A5001322907 @default.
• W2585686985 creator A5004702687 @default.
• W2585686985 creator A5008872132 @default.
• W2585686985 creator A5009431453 @default.
• W2585686985 creator A5011528890 @default.
• W2585686985 creator A5012582986 @default.
• W2585686985 creator A5014873864 @default.
• W2585686985 creator A5016021684 @default.
• W2585686985 creator A5019949455 @default.
• W2585686985 creator A5022712318 @default.
• W2585686985 creator A5026546201 @default.
• W2585686985 creator A5027438281 @default.
• W2585686985 creator A5029573906 @default.
• W2585686985 creator A5038749239 @default.
• W2585686985 creator A5051520180 @default.
• W2585686985 creator A5060770003 @default.
• W2585686985 creator A5064436213 @default.
• W2585686985 creator A5067811984 @default.
• W2585686985 creator A5076859301 @default.
• W2585686985 creator A5080385460 @default.
• W2585686985 creator A5088764253 @default.
• W2585686985 date "2015-12-03" @default.
• W2585686985 modified "2023-10-18" @default.
• W2585686985 title "Early Response Does Not Impact on the Long-Term Outcome of Children and Adolescents with Chronic Myeloid Leukemia Treated with High-Dose Imatinib. the Italian Experience" @default.
• W2585686985 doi "https://doi.org/10.1182/blood.v126.23.2788.2788" @default.
• W2585686985 hasPublicationYear "2015" @default.
• W2585686985 type Work @default.
• W2585686985 sameAs 2585686985 @default.
• W2585686985 citedByCount "0" @default.
• W2585686985 crossrefType "journal-article" @default.
• W2585686985 hasAuthorship W2585686985A5001322907 @default.
• W2585686985 hasAuthorship W2585686985A5004702687 @default.
• W2585686985 hasAuthorship W2585686985A5008872132 @default.
• W2585686985 hasAuthorship W2585686985A5009431453 @default.
• W2585686985 hasAuthorship W2585686985A5011528890 @default.
• W2585686985 hasAuthorship W2585686985A5012582986 @default.
• W2585686985 hasAuthorship W2585686985A5014873864 @default.
• W2585686985 hasAuthorship W2585686985A5016021684 @default.
• W2585686985 hasAuthorship W2585686985A5019949455 @default.
• W2585686985 hasAuthorship W2585686985A5022712318 @default.
• W2585686985 hasAuthorship W2585686985A5026546201 @default.
• W2585686985 hasAuthorship W2585686985A5027438281 @default.
• W2585686985 hasAuthorship W2585686985A5029573906 @default.
• W2585686985 hasAuthorship W2585686985A5038749239 @default.
• W2585686985 hasAuthorship W2585686985A5051520180 @default.
• W2585686985 hasAuthorship W2585686985A5060770003 @default.
• W2585686985 hasAuthorship W2585686985A5064436213 @default.
• W2585686985 hasAuthorship W2585686985A5067811984 @default.
• W2585686985 hasAuthorship W2585686985A5076859301 @default.
• W2585686985 hasAuthorship W2585686985A5080385460 @default.
• W2585686985 hasAuthorship W2585686985A5088764253 @default.
• W2585686985 hasConcept C104317684 @default.
• W2585686985 hasConcept C126322002 @default.
• W2585686985 hasConcept C138626823 @default.
• W2585686985 hasConcept C143998085 @default.
• W2585686985 hasConcept C203014093 @default.
• W2585686985 hasConcept C2777583451 @default.
• W2585686985 hasConcept C2778729363 @default.
• W2585686985 hasConcept C2778904597 @default.
• W2585686985 hasConcept C2908647359 @default.
• W2585686985 hasConcept C3019892230 @default.
• W2585686985 hasConcept C55493867 @default.
• W2585686985 hasConcept C71924100 @default.
• W2585686985 hasConcept C72563966 @default.
• W2585686985 hasConcept C86803240 @default.
• W2585686985 hasConcept C90924648 @default.
• W2585686985 hasConcept C99454951 @default.
• W2585686985 hasConceptScore W2585686985C104317684 @default.
• W2585686985 hasConceptScore W2585686985C126322002 @default.
• W2585686985 hasConceptScore W2585686985C138626823 @default.
• W2585686985 hasConceptScore W2585686985C143998085 @default.
• W2585686985 hasConceptScore W2585686985C203014093 @default.
• W2585686985 hasConceptScore W2585686985C2777583451 @default.
• W2585686985 hasConceptScore W2585686985C2778729363 @default.
• W2585686985 hasConceptScore W2585686985C2778904597 @default.
• W2585686985 hasConceptScore W2585686985C2908647359 @default.
• W2585686985 hasConceptScore W2585686985C3019892230 @default.
• W2585686985 hasConceptScore W2585686985C55493867 @default.
• W2585686985 hasConceptScore W2585686985C71924100 @default.
• W2585686985 hasConceptScore W2585686985C72563966 @default.
• W2585686985 hasConceptScore W2585686985C86803240 @default.
• W2585686985 hasConceptScore W2585686985C90924648 @default.
• W2585686985 hasConceptScore W2585686985C99454951 @default.
• W2585686985 hasLocation W25856869851 @default.
• W2585686985 hasOpenAccess W2585686985 @default.
• W2585686985 hasPrimaryLocation W25856869851 @default.
• W2585686985 hasRelatedWork W1801154922 @default.
• W2585686985 hasRelatedWork W1857376095 @default.
• W2585686985 hasRelatedWork W1996542562 @default.
• W2585686985 hasRelatedWork W2030447123 @default.
• W2585686985 hasRelatedWork W2101217932 @default.
• W2585686985 hasRelatedWork W2109339644 @default.
• W2585686985 hasRelatedWork W2130286859 @default.
• W2585686985 hasRelatedWork W2201431880 @default.
• W2585686985 hasRelatedWork W2510598749 @default.
• W2585686985 hasRelatedWork W2524074492 @default.
• W2585686985 hasRelatedWork W2527518979 @default.
• W2585686985 hasRelatedWork W2530211979 @default.

• next